FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2939067612> ?p ?o ?g. }

• W2939067612 endingPage "e000889" @default.
• W2939067612 startingPage "e000889" @default.
• W2939067612 abstract "Objectives Glucocorticoids have anti-inflammatory, transrepression-mediated effects, although adverse events (AEs; transactivation-mediated effects) limit long-term use in patients with rheumatoid arthritis (RA). We evaluated the efficacy and safety of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, versus prednisone or placebo. Methods In this 12-week, phase II, randomised controlled trial, 323 patients with moderate to severe RA were randomised 1:1:1:1:1:1:1 to fosdagrocorat (1 mg, 5 mg, 10 mg or 15 mg), prednisone (5 mg or 10 mg) or placebo, once daily. The primary endpoints (week 8) were American College of Rheumatology 20% improvement criteria (ACR20) responses, and percentage changes from baseline in biomarkers of bone formation (procollagen type 1 N-terminal peptide [P1NP]) and resorption (urinary N-telopeptide to urinary creatinine ratio [uNTx:uCr]). Safety was assessed. Results ACR20 responses with fosdagrocorat 10 mg and 15 mg were superior to placebo, and fosdagrocorat 15 mg was non-inferior to prednisone 10 mg (week 8 model-predicted ACR20 responses: 47%, 61%, 69% and 73% vs 51%, 71% and 37% with fosdagrocorat 1 mg, 5 mg, 10 mg and 15 mg vs prednisone 5 mg, 10 mg and placebo, respectively). Percentage changes from baseline in P1NP with fosdagrocorat 1 mg, 5 mg and 10 mg met non-inferiority criteria to prednisone 5 mg. Corresponding changes in uNTx:uCr varied considerably. All fosdagrocorat doses reduced glycosylated haemoglobin levels. AEs were similar between groups; 63 (19.5%) patients reported treatment-related AEs; 9 (2.8%) patients reported serious AEs. No patients had adrenal insufficiency, treatment-related significant infections or laboratory abnormalities. No deaths were reported. Conclusion In patients with RA, fosdagrocorat 10 mg and 15 mg demonstrated efficacy similar to prednisone 10 mg and safety similar to prednisone 5 mg. Trial registration number NCT01393639" @default.
• W2939067612 created "2019-04-25" @default.
• W2939067612 creator A5006137744 @default.
• W2939067612 creator A5010870801 @default.
• W2939067612 creator A5012283576 @default.
• W2939067612 creator A5024958150 @default.
• W2939067612 creator A5056552464 @default.
• W2939067612 creator A5058094909 @default.
• W2939067612 creator A5059124438 @default.
• W2939067612 creator A5059282099 @default.
• W2939067612 creator A5068487815 @default.
• W2939067612 date "2019-04-01" @default.
• W2939067612 modified "2023-10-17" @default.
• W2939067612 title "Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study" @default.
• W2939067612 cites W1831778092 @default.
• W2939067612 cites W1980642334 @default.
• W2939067612 cites W1993799371 @default.
• W2939067612 cites W1995887221 @default.
• W2939067612 cites W2010039853 @default.
• W2939067612 cites W2051391060 @default.
• W2939067612 cites W2057430367 @default.
• W2939067612 cites W2069452057 @default.
• W2939067612 cites W2071782474 @default.
• W2939067612 cites W2080874810 @default.
• W2939067612 cites W2081734937 @default.
• W2939067612 cites W2099866582 @default.
• W2939067612 cites W2108134938 @default.
• W2939067612 cites W2114800482 @default.
• W2939067612 cites W2131517206 @default.
• W2939067612 cites W2133744202 @default.
• W2939067612 cites W2136255927 @default.
• W2939067612 cites W2143212689 @default.
• W2939067612 cites W2145390209 @default.
• W2939067612 cites W2151888386 @default.
• W2939067612 cites W2154341553 @default.
• W2939067612 cites W2159896475 @default.
• W2939067612 cites W2160936253 @default.
• W2939067612 cites W2163363994 @default.
• W2939067612 cites W2170149822 @default.
• W2939067612 cites W2180685702 @default.
• W2939067612 cites W2227769517 @default.
• W2939067612 cites W2292748966 @default.
• W2939067612 cites W2321044345 @default.
• W2939067612 cites W2340298857 @default.
• W2939067612 cites W2561724307 @default.
• W2939067612 cites W2564688248 @default.
• W2939067612 cites W2566839077 @default.
• W2939067612 cites W45832520 @default.
• W2939067612 doi "https://doi.org/10.1136/rmdopen-2018-000889" @default.
• W2939067612 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6525626" @default.
• W2939067612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31168411" @default.
• W2939067612 hasPublicationYear "2019" @default.
• W2939067612 type Work @default.
• W2939067612 sameAs 2939067612 @default.
• W2939067612 citedByCount "24" @default.
• W2939067612 countsByYear W29390676122019 @default.
• W2939067612 countsByYear W29390676122020 @default.
• W2939067612 countsByYear W29390676122021 @default.
• W2939067612 countsByYear W29390676122022 @default.
• W2939067612 countsByYear W29390676122023 @default.
• W2939067612 crossrefType "journal-article" @default.
• W2939067612 hasAuthorship W2939067612A5006137744 @default.
• W2939067612 hasAuthorship W2939067612A5010870801 @default.
• W2939067612 hasAuthorship W2939067612A5012283576 @default.
• W2939067612 hasAuthorship W2939067612A5024958150 @default.
• W2939067612 hasAuthorship W2939067612A5056552464 @default.
• W2939067612 hasAuthorship W2939067612A5058094909 @default.
• W2939067612 hasAuthorship W2939067612A5059124438 @default.
• W2939067612 hasAuthorship W2939067612A5059282099 @default.
• W2939067612 hasAuthorship W2939067612A5068487815 @default.
• W2939067612 hasBestOaLocation W29390676121 @default.
• W2939067612 hasConcept C126322002 @default.
• W2939067612 hasConcept C126894567 @default.
• W2939067612 hasConcept C134018914 @default.
• W2939067612 hasConcept C142724271 @default.
• W2939067612 hasConcept C168563851 @default.
• W2939067612 hasConcept C197934379 @default.
• W2939067612 hasConcept C198451711 @default.
• W2939067612 hasConcept C203092338 @default.
• W2939067612 hasConcept C204787440 @default.
• W2939067612 hasConcept C27081682 @default.
• W2939067612 hasConcept C2777575956 @default.
• W2939067612 hasConcept C2778720950 @default.
• W2939067612 hasConcept C2780306776 @default.
• W2939067612 hasConcept C71924100 @default.
• W2939067612 hasConcept C90924648 @default.
• W2939067612 hasConceptScore W2939067612C126322002 @default.
• W2939067612 hasConceptScore W2939067612C126894567 @default.
• W2939067612 hasConceptScore W2939067612C134018914 @default.
• W2939067612 hasConceptScore W2939067612C142724271 @default.
• W2939067612 hasConceptScore W2939067612C168563851 @default.
• W2939067612 hasConceptScore W2939067612C197934379 @default.
• W2939067612 hasConceptScore W2939067612C198451711 @default.
• W2939067612 hasConceptScore W2939067612C203092338 @default.
• W2939067612 hasConceptScore W2939067612C204787440 @default.
• W2939067612 hasConceptScore W2939067612C27081682 @default.
• W2939067612 hasConceptScore W2939067612C2777575956 @default.
• W2939067612 hasConceptScore W2939067612C2778720950 @default.

• next